Genetic risk stratification, pivotal to precluding the CAD pandemic

References

[1] Stranger BE,Dunning M.Relative impact of nucleotide and copy number variation on gene expression phenotypes.Science2007;315:848-53 PMCID:PMC2665772

[2] McPherson R,Kavaslar N.A common allele on chromosome 9 associated with coronary heart disease.Science2007;316:1488-91 PMCID:PMC2711874

[3] Helgadottir A,Manolescu A.A common variant on chromosome 9p21 affects the risk of myocardial infarction.Science2007;316:1491-3

[4] Assimes TL.Genetics: implications for prevention and management of coronary artery disease.J Am Coll Cardiol2016;68:2797-818

[5] Schunkert H,Kessler T,Zeng L.Genetics of coronary artery disease in the light of genome-wide association studies.Clin Res Cardiol2018;107:2-9

[6] Roberts R.Clinical application of genetic prediction in the management of CAD.IJIRMS2021;6:46-52

[7] Davies RW,Stewart AF.Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies.Circ Cardiovasc Genet2010;3:468-74 PMCID:PMC3035486

[8] Abraham G,Bhalala OG.Genomic prediction of coronary heart disease.Eur Heart J2016;37:3267-78 PMCID:PMC5146693

[9] Inouye M,Nelson CP.Genomic risk prediction of coronary artery disease in 480,000 adults.J Am Coll Cardiol2018;72:1883-93 PMCID:PMC6176870

[10] Khera AV,Aragam KG.Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations.Nat Genet2018;50:1219-24 PMCID:PMC6128408

[11] Mega JL,Smith JG.Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.Lancet2015;385:2264-71 PMCID:PMC4608367

[12] Natarajan P,Stitziel NO.Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting.Circulation2017;135:2091-101 PMCID:PMC5484076

[13] Marston NA,Nordio F.Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score.Circulation2020;141:616-23 PMCID:PMC8058781

[14] Damask A,Schwartz GG.Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial.Circulation2020;141:624-36

[15] Khera AV,Drake I.Genetic risk, adherence to a healthy lifestyle, and coronary disease.N Engl J Med2016;375:2349-58 PMCID:PMC5338864

[16] Tikkanen E,Ingelsson E.Associations of fitness, physical activity, strength, and genetic risk with cardiovascular disease: longitudinal analyses in the UK Biobank study.Circulation2018;137:2583-91 PMCID:PMC5997501

[17] Riveros-Mckay F,Moore R.Integrated polygenic tool substantially enhances coronary artery disease prediction.Circ Genom Precis Med2021;14:e003304